Clinical Trial Update: TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TQB2450 plus anlotinib as adjuvant therapy for hepatocellular carcinoma at high risk of recurrence after surgical resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Xianhai Mao | Conditions: Hepatocellular Carcinoma, Adjuvant Therapy | Phase 2 | Status: UNKNOWN